/PRNewswire/ Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today.
By exploiting dual specificity to ever greater effect, bispecific antibodies expand possibilities for Treg depletion, checkpoint inhibition, and targeted toxicity.
By exploiting dual specificity to ever greater effect, bispecific antibodies expand possibilities for Treg depletion, checkpoint inhibition, and targeted toxicity.
The PD-1 and PD-L1 inhibitors market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in healthcare spending across the world. In